A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation
Open Access
- 16 February 2024
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (4) , 936-946
Abstract
Thrombosis is an important manifestation of the antiphospholipid syndrome (APS). The thrombin generation (TG) test is a global hemostasis assay, and increased TG is associated with thrombosis. APS is currently diagnosed based on clinical and laboratory criteria, the latter defined as anti-cardiolipin, anti–β2-glycoprotein I antibodies, or lupus anticoagulant (LA). APS testing is often performed after a thrombotic episode and subsequent administration of anticoagulation, which might hamper the interpretation of clotting assays used for LA testing. We set out to develop an artificial neural network (NN) that can diagnose APS in patients who underwent vitamin K antagonist (VKA) treatment, based on TG test results. Five NNs were trained to diagnose APS in 48 VKA-treated patients with APS and 64 VKA-treated controls, using TG and thrombin dynamics parameters as inputs. The 2 best-performing NNs were selected (accuracy, 96%; sensitivity, 96%-98%; and specificity, 95%-97%) and further validated in an independent cohort of VKA-anticoagulated patients with APS (n = 33) and controls (n = 62). Independent clinical validation favored 1 of the 2 selected NNs, with a sensitivity of 88% and a specificity of 94% for the diagnosis of APS. In conclusion, the combined use of TG and NN methodology allowed for us to develop an NN that diagnoses APS with an accuracy of 92% in individuals with VKA anticoagulation (n = 95). After further clinical validation, the NN could serve as a screening and diagnostic tool for patients with thrombosis, especially because there is no need to interrupt anticoagulant therapy.Keywords
This publication has 40 references indexed in Scilit:
- Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti-Beta2-Glycoprotein I IgG ELISAsPLOS ONE, 2013
- Internal Quality Control and External Quality Assurance in Testing for Antiphospholipid Antibodies: Part I—Anticardiolipin and Anti-β2-Glycoprotein I AntibodiesSeminars in Thrombosis and Hemostasis, 2012
- Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2010
- Update of the guidelines for lupus anticoagulant detectionJournal of Thrombosis and Haemostasis, 2009
- Coagulation factors and the protein C system as determinants of thrombin generation in a normal populationJournal of Thrombosis and Haemostasis, 2007
- Activated protein C resistance determined with a thrombin generation‐based test is associated with thrombotic events in patients with lupus anticoagulantsJournal of Thrombosis and Haemostasis, 2007
- Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrenceBritish Journal of Haematology, 2007
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Anti–β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndromeBlood, 2003
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999